Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant–Positive Non–Small Cell Lung Cancer

医学 肿瘤科 内科学 队列 肺癌 表皮生长因子受体 癌症 阶段(地层学) 古生物学 生物
作者
Jiangdian Song,Lu Wang,Nathan Ng,Mingfang Zhao,Jingyun Shi,Ning Wu,Weimin Li,Zaiyi Liu,Kristen W. Yeom,Jie Tian
出处
期刊:JAMA network open [American Medical Association]
卷期号:3 (12): e2030442-e2030442 被引量:58
标识
DOI:10.1001/jamanetworkopen.2020.30442
摘要

Importance

An end-to-end efficacy evaluation approach for identifying progression risk after epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) therapy in patients with stage IVEGFRvariant–positive non–small cell lung cancer (NSCLC) is lacking.

Objective

To propose a clinically applicable large-scale bidirectional generative adversarial network for predicting the efficacy of EGFR-TKI therapy in patients with NSCLC.

Design, Setting, and Participants

This diagnostic/prognostic study enrolled 465 patients from January 1, 2010, to August 1, 2017, with follow-up from February 1, 2010, to June 1, 2020. A deep learning (DL) semantic signature to predict progression-free survival (PFS) was constructed in the training cohort, validated in 2 external validation and 2 control cohorts, and compared with the radiomics signature.

Exposures

An end-to-end bidirectional generative adversarial network framework was designed to predict the progression risk in patients with NSCLC.

Main Outcomes and Measures

The primary end point was PFS, considering the time from the initiation of therapy to the date of recurrence, confirmed disease progression, or death.

Results

A total of 342 patients with stage IVEGFRvariant–positive NSCLC receiving EGFR-TKI therapy met the inclusion criteria. Of these, 145 patients from 2 of the hospitals (n = 117 and 28) formed a training cohort (mean [SD] age, 61 [11] years; 87 [60.0%] female), and the patients from 2 other hospitals comprised 2 external validation cohorts (validation cohort 1: n = 101; mean [SD] age, 57 [12] years; 60 [59.4%] female; and validation cohort 2: n = 96, mean [SD] age, 58 [9] years; 55 [57.3%] female). Fifty-six patients with advanced-stageEGFRvariant–positive NSCLC (mean [SD] age, 52 [11] years; 26 [46.4%] female) and 67 patients with advanced-stageEGFRwild-type NSCLC (mean [SD] age, 54 [10] years; 10 [15.0%] female) who received first-line chemotherapy were included. A total of 90 (26%) receiving EGFR-TKI therapy with a high risk of rapid disease progression were identified (median [range] PFS, 7.3 [1.4-32.0] months in the training cohort, 5.0 [0.6-34.6] months in validation cohort 1, and 6.4 [1.8-20.1] months, in validation cohort 2) using the DL semantic signature.The PFS decreased by 36% (hazard ratio, 2.13; 95% CI, 1.30-3.49;P < .001) compared with that in other patients (median [range] PFS, 11.5 [1.5-64.2] months in the training cohort, 10.9 [1.1-50.5] in validation cohort 1, and 8.9 [0.8-40.6] months in validation cohort 2. No significant differences were observed when comparing the PFS of high-risk patients receiving EGFR-TKI therapy with the chemotherapy cohorts (median PFS, 6.9 vs 4.4 months;P = .08). In terms of predicting the tumor progression risk after EGFR-TKI therapy, clinical decisions based on the DL semantic signature led to better survival outcomes than those based on radiomics signature across all risk probabilities by the decision curve analysis.

Conclusions and Relevance

This diagnostic/prognostic study provides a clinically applicable approach for identifying patients with stage IVEGFRvariant–positive NSCLC who are not likely to benefit from EGFR-TKI therapy. The end-to-end DL-derived semantic features eliminated all manual interventions required while using previous radiomics methods and have a better prognostic performance.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
从容小鸽子完成签到,获得积分10
刚刚
刚刚
内向的博超完成签到,获得积分10
1秒前
1秒前
peanut完成签到,获得积分10
1秒前
molihuakai的应助被丨小桉柠采纳,获得10
1秒前
molik完成签到,获得积分10
2秒前
这篇论文就发个尊贵的顶就好完成签到 ,获得积分10
2秒前
2秒前
dtmxf发布了新的文献求助10
2秒前
欣慰小蕊完成签到,获得积分10
2秒前
秋风的应助被fxl采纳,获得20
2秒前
KX完成签到,获得积分10
3秒前
3秒前
xttttttt完成签到,获得积分10
3秒前
3秒前
ding的应助被HHMTT采纳,获得10
3秒前
嘻嘻发布了新的文献求助10
3秒前
失眠世立完成签到 ,获得积分10
4秒前
山与海完成签到,获得积分10
5秒前
共享精神的应助被旋风狗超人采纳,获得10
5秒前
6秒前
旺旺发布了新的文献求助10
6秒前
lixue1993发布了新的文献求助10
6秒前
余香的应助被lilili采纳,获得10
6秒前
sun完成签到,获得积分10
6秒前
6秒前
追寻若南完成签到,获得积分10
7秒前
噜噜噜的应助被不是夏娃采纳,获得10
7秒前
Akim的应助被甄明硕采纳,获得10
8秒前
8秒前
8秒前
稳重盼夏发布了新的文献求助10
8秒前
锡嘻完成签到 ,获得积分10
8秒前
FFFFFFG发布了新的文献求助10
9秒前
9秒前
9秒前
9秒前
沉默的幻枫完成签到,获得积分10
9秒前
柏舟完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8174387
求助须知:如何正确求助?哪些是违规求助? 9566467
关于积分的说明 21786460
捐赠科研通 7768617
什么是DOI,文献DOI怎么找? 3431710
关于科研通互助平台的介绍 2555912
邀请新用户注册赠送积分活动 2477039